This prospective observational cohort study evaluates a community-based supervised exercise oncology program delivered in real-world settings in Madrid, Spain. The program is designed for adults with a cancer diagnosis across the cancer continuum, including survivors, patients undergoing active treatment, individuals receiving hormonotherapy, and patients with metastatic disease. Participants take part in a structured multimodal exercise program combining aerobic, resistance, and functional training, delivered in supervised group-based sessions either in person or through synchronous online formats. The primary aims of the study are to assess program adherence, health-related quality of life, fatigue, and cost-effectiveness, expressed as quality-adjusted life years (QALYs). Secondary outcomes include cardiorespiratory fitness, muscular strength, functional capacity, physical activity levels, body composition, and psychological well-being. Assessments are conducted at baseline and every four months over a 12-month follow-up period. This study provides real-world evidence on the feasibility, clinical impact, and economic value of community-based exercise oncology programs across different stages of the cancer trajectory.
This study is a prospective observational cohort analysis of adults with a confirmed cancer diagnosis participating in a community-based supervised exercise oncology program in Madrid, Spain. Participants are referred by oncology specialists or self-referred with medical clearance to engage in moderate-intensity physical exercise. The intervention consists of supervised multimodal exercise sessions lasting approximately 75 minutes, including warm-up, combined aerobic and resistance training, and cool-down periods. Aerobic training is prescribed using heart rate reserve and perceived exertion scales, while resistance training includes free-weight and functional exercises targeting major muscle groups. Sessions are delivered in small groups either face-to-face or via synchronous online platforms, with individualized progression and safety monitoring. Participants undergo standardized assessments at baseline and at 4, 8, and 12 months. Primary outcomes include adherence to supervised exercise sessions, health-related quality of life, fatigue, and cost-effectiveness measured through quality-adjusted life years derived from EQ-5D instruments. Secondary outcomes include estimated cardiorespiratory fitness, muscular strength, functional capacity tests, physical activity behavior, body composition, and psychological outcomes. The study aims to generate real-world evidence on the feasibility, effectiveness, and economic impact of integrating structured exercise programs into community-based cancer care across different clinical stages of disease.
Study Type
OBSERVATIONAL
Enrollment
492
Ejercicio y Cáncer Center
Madrid, Madrid, Spain
Adherence
Percentage of supervised exercise sessions completed out of scheduled sessions.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Health-related quality of life (FACT-G)
Health-related quality of life (units on a scale) assessed using the Functional Assessment of Cancer Therapy - General (FACT-G)
Time frame: Baseline, 4 months, 8 months, and 12 months.
Fatigue (FACT-F)
Fatigue (units on a scale) assessed using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACT-F).
Time frame: Baseline, 4 months, 8 months, and 12 months.
Quality-adjusted life years (QALYs)
Quality-adjusted life years calculated by integrating EQ-5D utility scores collected at multiple time points over the 12-month follow-up period. Repeated EQ-5D measurements are aggregated to derive a single QALY value per participant.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Barriers to participation
Using a structured questionnaire based on previously published frameworks on determinants of adherence in cancer survivors.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Estimated VO₂max
Estimated maximal oxygen uptake (VO₂max) assessed using the Bruce treadmill protocol and Mackenzie equation.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Muscular strength
Upper- and lower-limb muscular strength (kg) estimated using submaximal tests to estimate one-repetition maximum (1RM).
Time frame: Baseline, 4 months, 8 months, and 12 months.
Functional capacity
Functional capacity assessed using the 6-Minute Walk Test (6MWT) in meters.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Functional capacity
Functional capacity assessed using the 30-second Sit-to-Stand test (repetitions)
Time frame: Baseline, 4 months, 8 months, and 12 months.
Body weight (kg)
Body weight assessed by bioelectrical impedance analysis using the Tanita MC-601F.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Body Fat Percentage (%)
Body Fat Percentage (%) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Time frame: Baseline, 4 months, 8 months, and 12 months.
Fat Mass (kg)
Fat Mass (kg) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Time frame: Baseline, 4 months, 8 months, and 12 months.
Lean Mass Percentage (%)
Lean Mass Percentage (%) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Time frame: Baseline, 4 months, 8 months, and 12 months.
Lean Mass (kg)
Lean Mass (kg) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Time frame: Baseline, 4 months, 8 months, and 12 months.
Physical activity
Physical activity levels assessed using the International Physical Activity Questionnaire (IPAQ). The IPAQ estimates total physical activity expressed as metabolic equivalent minutes per week (MET-min/week), calculated from self-reported frequency, duration, and intensity of physical activity. Scores range from 0 MET-min/week to no upper limit, with higher values indicating higher levels of physical activity.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Anxiety (HADS-A)
Symptoms of anxiety (units on a scale) assessed using the Hospital Anxiety Scale (HADS-A) The HADS-A consists of 7 items scored from 0 to 3, yielding a total score ranging from 0 to 21, with higher scores indicating greater severity of anxiety symptoms.
Time frame: Baseline, 4 months, 8 months, and 12 months.
Depression (HADS-D)
Depressive symptoms assessed using the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D). The HADS-D consists of 7 items scored from 0 to 3, yielding a total score ranging from 0 to 21, with higher scores indicating greater severity of depressive symptoms.
Time frame: Baseline, 4 months, 8 months, and 12 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.